# TB-500 Peptide

> TB-500 is a synthetic thymosin beta-4 fragment that acts on cell migration, angiogenesis, wound-repair signaling, and soft-tissue remodeling.

Canonical: https://pepflow.app/peptides/tb-500/

The Mobility Signal

A synthetic N-acetylated LKKTETQ fragment associated with thymosin beta-4 repair biology, best known in peptide-market use for soft-tissue recovery claims but supported mainly by thymosin beta-4 mechanism, local wound and eye research, anti-doping detection work, and limited direct TB-500 human research activity.

Soft-tissue recovery  Inflammation support  Muscle repair

Tier C

Evidence Emerging

Safety Limited Data

FDA status Not Approved

Topical 503A Not Listed

Last reviewed October 25, 2026 28 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is TB-500?

TB-500 usually refers to a synthetic N-acetylated LKKTETQ peptide. The LKKTETQ segment corresponds to amino acids 17-23 of thymosin beta-4, a small endogenous beta-thymosin protein involved in actin binding, cell movement, inflammation signaling, and repair biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)

The identity boundary matters. Full-length thymosin beta-4 has human studies in ophthalmic, dermal-wound, intravenous safety, and cardiac-development programs, while commercial TB-500 products are usually discussed as the shorter fragment. Those source streams are related, but they are not interchangeable.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

The practical interest comes from thymosin beta-4 biology: repair literature connects the parent peptide with cell migration, angiogenesis, anti-inflammatory effects, anti-apoptotic signaling, and wound repair. In plain terms, the research question is whether a peptide signal can help injured tissue coordinate movement, blood-vessel support, and remodeling.[\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/26096726/>)

In sports and recovery communities, TB-500 is often discussed beside BPC-157. That pairing is common in logs and clinics, but the combination has not been validated as a controlled human recovery stack, and TB-500 has a separate anti-doping and FDA compounding risk profile.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) For more context, read the [TB-500 and thymosin beta-4 naming explainer](<https://pepflow.app/blog/tb-4-frag-500/>).

## What TB-500 is investigated for

TB-500 evidence is grouped by practical use case and injectable and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Wound healing and ocular repair Topical 52% Emerging

Full-length thymosin beta-4 data support wound and ocular repair signals, while route, product, and molecule identity limit transfer to TB-500.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>)

#### Human evidence

Human full-length thymosin beta-4 research includes dry-eye studies, local wound studies, and IV safety work. These support parent-peptide translation but do not validate all TB-500 fragment products.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/25826322/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[11\]](<https://clinicaltrials.gov/study/NCT00832091>)

#### Animal / mechanistic evidence

Corneal and dermal reviews describe thymosin beta-4 effects on epithelial migration, inflammation, apoptosis, angiogenesis, and wound repair.[\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>)

### ### Cardiac tissue repair Injectable 50% Emerging

Cardiac tissue repair has limited human thymosin beta-4 signal and active TB-500 trial activity, but direct TB-500 fragment benefit for heart disease is unproven.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[27\]](<https://pubmed.ncbi.nlm.nih.gov/41229390/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/31333080/>)

#### Human evidence

A Phase 1/2 TB-500 fragment study is recruiting adults with stable ASCVD and has no posted results. A randomized recombinant full-length thymosin beta-4 STEMI report found an early infarct-area signal, but overall infarct-area differences across the full sample were not significant and the molecule was not TB-500 fragment.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[27\]](<https://pubmed.ncbi.nlm.nih.gov/41229390/>) [\[21\]](<https://clinicaltrials.gov/study/NCT05485818>)

#### Animal / mechanistic evidence

Cardiac repair reviews and the recombinant thymosin beta-4 translational study describe cardioprotection, neovascularization, inflammation modulation, apoptosis signaling, and remodeling biology.[\[20\]](<https://pubmed.ncbi.nlm.nih.gov/31333080/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[27\]](<https://pubmed.ncbi.nlm.nih.gov/41229390/>)

### ### Soft-tissue recovery Injectable 42% Preliminary

TB-500 has a plausible recovery rationale, but proven injury-repair or performance outcomes in people have not been established.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

#### Human evidence

Direct human evidence for TB-500 injury recovery remains limited. An independent improvement in healing or function has not been established.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/42876687/>)

#### Animal / mechanistic evidence

The biological rationale comes from thymosin beta-4 repair literature involving actin, cell migration, angiogenesis, anti-inflammatory effects, and tissue remodeling.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)

### ### Tendon and ligament repair Injectable 34% Limited

Tendon and ligament repair has animal thymosin beta-4 support; controlled human TB-500 fragment efficacy has not been established.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/23523891/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>)

#### Human evidence

No controlled human TB-500 fragment trial has established tendon or ligament repair outcomes. The direct TB-500 trial activity identified here is cardiovascular-biomarker focused, not musculoskeletal injury focused.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Animal / mechanistic evidence

A rat medial-collateral-ligament model reported improved histologic organization and biomechanical healing after local thymosin beta-4 treatment, supporting plausibility for ligament repair biology rather than proving fragment efficacy in people.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/23523891/>)

### ### Alzheimer's-related neuroprotection Injectable 34% Limited

Alzheimer's-related neuroprotection has cell, organoid, and mouse-model support, but human cognitive or dementia outcomes have not been established.[\[25\]](<https://pubmed.ncbi.nlm.nih.gov/41443105/>) [\[26\]](<https://pubmed.ncbi.nlm.nih.gov/40816274/>)

#### Human evidence

No human TB-500 or thymosin beta-4 clinical outcome trial was identified for Alzheimer's disease or neuroprotection.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

#### Animal / mechanistic evidence

Recent Alzheimer's model studies reported that thymosin beta-4 or thymosin beta-4-derived peptides, including TB500, affected neuroinflammation, neurite atrophy, neuronal survival, and memory-related outcomes in organoid, cell, and 5xFAD mouse models.[\[25\]](<https://pubmed.ncbi.nlm.nih.gov/41443105/>) [\[26\]](<https://pubmed.ncbi.nlm.nih.gov/40816274/>)

### ### Muscle repair and recovery Injectable 32% Limited

Muscle repair has thymosin beta-4 mechanism support, but controlled human TB-500 muscle-recovery outcomes have not been shown.[\[19\]](<https://pubmed.ncbi.nlm.nih.gov/20880960/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Human evidence

No controlled human TB-500 fragment study was identified for muscle recovery, return to training, strength recovery, or performance outcomes.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Animal / mechanistic evidence

A skeletal-muscle regeneration study found thymosin beta-4 expression increased early after injury and that thymosin beta-4 or its sulfoxized form promoted myoblast chemotaxis and wound closure in experimental models.[\[19\]](<https://pubmed.ncbi.nlm.nih.gov/20880960/>)

### ### Reduced inflammation and fibrosis Injectable 32% Limited

Reduced inflammation and fibrosis are plausible from thymosin beta-4 signaling models, but clinical anti-inflammatory or anti-fibrotic TB-500 outcomes have not been established.[\[23\]](<https://pubmed.ncbi.nlm.nih.gov/26006229/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/36834849/>)

#### Human evidence

No controlled human TB-500 fragment study was identified that establishes reduced inflammation or fibrosis as a clinical outcome.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Animal / mechanistic evidence

Thymosin beta-4 literature connects the parent peptide with anti-inflammatory signaling and fibrotic remodeling, including hepatic stellate cell and NLRP3 inflammasome models.[\[23\]](<https://pubmed.ncbi.nlm.nih.gov/26006229/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/36834849/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)

### ### Hair regrowth Injectable 30% Limited

Hair regrowth has parent-peptide animal support, but human TB-500 scalp or hair-density outcomes have not been established.[\[22\]](<https://pubmed.ncbi.nlm.nih.gov/15037013/>)

#### Human evidence

No controlled human TB-500 fragment trial was identified for scalp hair growth, androgenetic alopecia, or hair-density outcomes.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Animal / mechanistic evidence

A thymosin beta-4 rodent study reported hair growth in normal and aged animals along with angiogenesis, cell migration, and wound-repair effects.[\[22\]](<https://pubmed.ncbi.nlm.nih.gov/15037013/>)

## Evidence snapshot

### Overall confidence

Emerging

52%

TB-500 is biologically plausible but not clinically settled. Human experience is stronger for full-length thymosin beta-4 products than for the marketed TB-500 fragment, and the direct TB-500 trial record has no posted outcomes.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

50%

### Human evidence

Emerging

Human evidence is strongest for full-length thymosin beta-4 products in dry-eye, wound, IV safety, and cardiac studies. Direct TB-500 fragment human outcome evidence remains limited, with no posted outcomes from the ASCVD biomarker trial.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/25826322/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[27\]](<https://pubmed.ncbi.nlm.nih.gov/41229390/>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

66%

### Animal / preclinical

Moderate

Preclinical support is the stronger part of the TB-500 story. Thymosin beta-4 and related fragment studies cover wound, ligament, muscle, fibrosis, hair-growth, cardiac, and Alzheimer's-model biology, but they do not prove fragment outcomes in people.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/23523891/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/20880960/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/15037013/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/36834849/>) [\[25\]](<https://pubmed.ncbi.nlm.nih.gov/41443105/>)

62%

### Mechanism support

Moderate

Mechanism support is coherent: thymosin beta-4 biology connects actin handling, cell migration, angiogenesis, anti-inflammatory signaling, anti-apoptotic signaling, and tissue remodeling. Fragment identity and route still limit direct transfer to TB-500 protocols.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>)

## Forms & administration

TB-500 is mostly discussed as an injectable fragment protocol, while full-length thymosin beta-4 has been studied as eye drops, dermal gel, and intravenous research products. These are separate administration categories with different evidence, sterility, dose, safety, and regulatory questions.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[11\]](<https://clinicaltrials.gov/study/NCT00832091>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

Injectable Topical

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Injectable recovery protocols commonly use 2–4 mg per dose.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Frequency

Injections are commonly used 2–3 times per week.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Timing Considerations

Injections are commonly timed after a workout or in the evening.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Cycle Length

Injectable cycles commonly run 4–8 weeks.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

[Full TB-500 dosage guide](<https://pepflow.app/peptides/tb-500/dosage/>)

## What to expect

### First week

Small functional changes: less stiffness, steadier soreness, or easier movement during everyday activity and rehab drills.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Weeks 2-4

Easier range of motion, steadier soreness, and better tolerance of rehab loads while the plan stays consistent.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Weeks 4-8

Clearer trend toward less pain, better mobility, and more reliable return-to-training tolerance.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### After stopping

Pain, mobility, and return-to-training tolerance should hold steady as rehab load and normal activity continue.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Safety profile

The safety profile is route- and identity-sensitive. Full-length thymosin beta-4 has limited human safety experience in specific trials, but FDA states it has not identified human exposure data for drug products containing thymosin beta-4 fragment (TB-500) and flags immunogenicity, impurity, API-characterization, and unresolved harm concerns.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/34346165/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/20536472/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Common side effects

- Injection-site irritation [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Cautions

- Unapproved drug[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>)
- Sports prohibited
- Injectable purity and sterility[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### What we don't know

The key unknowns are fragment-specific pharmacokinetics, long-term safety, immunogenicity by route, human recovery outcomes, and whether commercial products match studied material.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Who TB-500 is not for

Route-specific avoid and medical-review notes:

- **Competitive athletes**

  Athletes subject to WADA-aligned rules should avoid TB-500 because thymosin beta-4 derivatives including TB-500 are prohibited.
- **Active infection, surgery, or open wound**

  Open wounds, post-surgical sites, eye disease, and infections need medical care rather than self-directed TB-500 or thymosin beta-4 product use.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- **Pregnancy, breastfeeding, or pediatric use**

  Safety data are not adequate for elective TB-500 use during pregnancy, breastfeeding, or pediatric care.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- **Cancer or angiogenesis-sensitive conditions**

  Because thymosin beta-4 biology involves cell migration and angiogenesis, systemic use with cancer or unexplained growth is a theoretical medical-review issue, not a casual recovery decision.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Recovery-plan confounding**

  Changing rehab intensity, anti-inflammatory medication use, physical therapy, and TB-500 at the same time makes it hard to interpret pain or function changes.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- **Immune-active medications**

  Interactions with immunosuppressive or immune-active medications are not established, but the repair and inflammation biology makes medical review important.[\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Pairing notes

### Commonly included in these stacks

[**GLOW Stack** GLOW is a three-component recovery and skin-matrix stack built around BPC-157, TB-500, and GHK-Cu. It is used to frame soft-tissue repair, cell migration, collagen and extracellular-matrix remodeling, and post-procedure skin-support discussions. BPC-157 TB-500 GHK-Cu](<https://pepflow.app/stacks/glow-stack/>) [**KLOW Stack** KLOW is a four-component recovery, skin, and inflammation-support stack built around BPC-157, TB-500, GHK-Cu, and KPV. It is used to frame tissue repair, cell migration, skin-matrix remodeling, gut or barrier inflammation, and post-procedure support in one plan. BPC-157 TB-500 GHK-Cu KPV](<https://pepflow.app/stacks/klow-stack/>) [**Wolverine Stack** The Wolverine Stack is a two-component repair and mobility stack built around BPC-157 and TB-500. BPC-157 supplies the localized repair and cytoprotection rationale, while TB-500 supplies the thymosin beta-4-derived cell-migration and wound-healing rationale. The exact combination lacks controlled human outcome trials. BPC-157 TB-500](<https://pepflow.app/stacks/wolverine-stack/>)

### Related peptides

[BPC-157](<https://pepflow.app/peptides/bpc-157/>)

## Regulatory status

### United States

United States: not FDA-approved for human use as a drug. FDA's safety-risk page lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500, under nominated-but-withdrawn bulk drug substances with immunogenicity, impurity, API-characterization, absent human-exposure, and unresolved harm concerns.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · openFDA Drugs@FDA queries for TB-500 and thymosin beta-4 returned no matching approved drug product. The recruiting TB-500 trial is research activity, not approval.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) | Flagged · FDA's safety-risk page lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500, under nominated-but-withdrawn substances and flags immunogenicity, peptide-related impurity, API-characterization, absent human-exposure, and unresolved harm concerns.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) |
| Topical | Not Approved · No FDA-approved topical, ophthalmic, or dermal thymosin beta-4 or TB-500 drug product was identified in the reviewed openFDA query. Clinical trial listings do not equal FDA approval.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[12\]](<https://clinicaltrials.gov/study/NCT01393132>) [\[11\]](<https://clinicaltrials.gov/study/NCT00832091>) | Not Listed · The current 503A PDF review did not identify a topical/local thymosin beta-4 listing separate from the TB-500 fragment safety-risk entry. Local clinical-trial products should not be treated as compounded-drug clearance.[\[16\]](<https://www.fda.gov/media/94155/download>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) |

### Injectable

FDA drug approval

Not Approved

openFDA Drugs@FDA queries for TB-500 and thymosin beta-4 returned no matching approved drug product. The recruiting TB-500 trial is research activity, not approval.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

503A compounding

Flagged

FDA's safety-risk page lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500, under nominated-but-withdrawn substances and flags immunogenicity, peptide-related impurity, API-characterization, absent human-exposure, and unresolved harm concerns.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Topical

FDA drug approval

Not Approved

No FDA-approved topical, ophthalmic, or dermal thymosin beta-4 or TB-500 drug product was identified in the reviewed openFDA query. Clinical trial listings do not equal FDA approval.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[12\]](<https://clinicaltrials.gov/study/NCT01393132>) [\[11\]](<https://clinicaltrials.gov/study/NCT00832091>)

503A compounding

Not Listed

The current 503A PDF review did not identify a topical/local thymosin beta-4 listing separate from the TB-500 fragment safety-risk entry. Local clinical-trial products should not be treated as compounded-drug clearance.[\[16\]](<https://www.fda.gov/media/94155/download>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### International

International status is product-, route-, and claim-specific. No country-specific therapeutic approval outside the United States is established in the current sources; treat TB-500 as investigational unless a local regulator and product authorization say otherwise.

### Sports & competition

Sports competition: prohibited under WADA growth-factor-related rules. The prohibition covers thymosin beta-4 derivatives such as TB-500 and is relevant in and out of competition.

## How it works

Thymosin beta-4 biology starts with actin, a structural protein cells use to move and change shape. Repair cells need that movement to cover a wound, remodel tissue, and coordinate local healing.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)

The parent peptide is also discussed in angiogenesis, anti-inflammatory signaling, anti-apoptotic signaling, and scar biology. That creates a coherent repair rationale, especially for local eye and dermal research.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/27450738/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/26096726/>)

TB-500 adds a translation problem: the marketed compound is usually the N-acetylated LKKTETQ fragment. Fragment identity, product purity, and route-specific exposure decide how much parent-peptide biology can be assumed.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Research gaps & open questions

What the current literature has not yet settled about TB-500:

01

The recruiting human trial needs to publish results on the TB-500 fragment itself. Safety or blood-marker findings would still not show that it speeds injury recovery.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

02

The short TB-500 fragment and full-length thymosin beta-4 need separate studies; they may not reach the same tissues, last the same time, or have the same effects.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

03

Independent testing needs to show what TB-500 products actually contain, including their identity, strength, sterility, and important impurities.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

04

TB-500 and BPC-157 need to be studied together before anyone can know whether the combination improves recovery or adds new safety risks.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Common questions

### Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500 usually refers to the N-acetylated LKKTETQ fragment, while many human clinical studies used full-length thymosin beta-4 products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Is TB-500 FDA-approved?

No. The reviewed openFDA query returned no matching approved TB-500 or thymosin beta-4 drug product, and FDA lists the TB-500 fragment in compounding safety-risk materials.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Does TB-500 have human evidence for injury recovery?

Direct TB-500 fragment evidence for injury recovery is limited. The human literature is stronger for full-length thymosin beta-4 products in other routes and conditions, and one TB-500 trial is recruiting without posted results.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26056426/>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Is TB-500 banned in sport?

Yes. WADA lists thymosin beta-4 and derivatives such as TB-500 as prohibited, so athletes should not treat research-use or recovery labeling as a loophole.

### Is TB-500 plus BPC-157 proven to work better?

No controlled human trial has established the TB-500 plus BPC-157 combination as better than either compound alone. Combination-level efficacy, safety, dosing, and regulatory status need separate review.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Myths & misconceptions

### Myth

Any thymosin beta-4 study proves TB-500 works.

### Reality

Full-length thymosin beta-4 studies are relevant background, but TB-500 is usually the shorter N-acetylated LKKTETQ fragment. Molecule and route differences matter.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Myth

TB-500 is an approved recovery drug.

### Reality

It is not FDA-approved for recovery, injury, wound healing, cardiovascular disease, or performance use in the reviewed U.S. database query.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

### Myth

The BPC-157 plus TB-500 stack is clinically proven.

### Reality

The stack is common in recovery discussions, but combination-level human evidence, safety, dosing, stability, and regulatory status have not been established.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## History & discovery

TB-500 entered the peptide market through thymosin beta-4 repair biology and anti-doping attention around an acetylated LKKTETQ fragment. Full-length thymosin beta-4 has a separate clinical-development history in eye, wound, and cardiac programs.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/26096726/>)

Research characterized thymosin beta-4 as an abundant actin-binding peptide with roles in cell migration, tissue repair, angiogenesis, inflammation, and scar biology.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[4\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)

Anti-doping researchers described TB-500 as a veterinary preparation containing N-acetylated LKKTETQ and developed methods to detect the parent peptide and metabolites in equine samples.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>)

ClinicalTrials.gov lists a recruiting Phase 1/2 study of TB-500 in adults with stable atherosclerotic cardiovascular disease, focused on safety, tolerability, pharmacokinetics, and exploratory cardiovascular biomarkers.[\[10\]](<https://clinicaltrials.gov/study/NCT07487363>)

## Published research 28 citations

TB-500 research covers tissue-repair signaling, fragment identity and safety. Much of the repair evidence concerns full-length thymosin beta-4, so support for the fragment’s clinical recovery effects remains limited.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23084823/>) [\[10\]](<https://clinicaltrials.gov/study/NCT07487363>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/23523891/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/20880960/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/42876687/>)

- [\[1\] **Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry.** PubMed / Journal of Chromatography A, 2012-11-23. animal.](<https://pubmed.ncbi.nlm.nih.gov/23084823/>)
- [\[2\] **Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications.** PubMed / Expert Opinion on Biological Therapy, 2012-01. review.](<https://pubmed.ncbi.nlm.nih.gov/22074294/>)
- [\[3\] **Advances in the basic and clinical applications of thymosin beta4.** PubMed / Expert Opinion on Biological Therapy, 2015. review.](<https://pubmed.ncbi.nlm.nih.gov/26096726/>)
- [\[4\] **Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.** PMC / Clinical Ophthalmology, 2007. review.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)
- [\[5\] **Thymosin beta4 Promotes Dermal Healing.** PubMed / Vitamins and Hormones, 2016. review.](<https://pubmed.ncbi.nlm.nih.gov/27450738/>)
- [\[6\] **Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment model.** PubMed / Clinical Ophthalmology, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26056426/>)
- [\[7\] **Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.** PubMed / Cornea, 2015-05. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25826322/>)
- [\[8\] **A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers.** PubMed / Journal of Cellular and Molecular Medicine, 2021-09. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34346165/>)
- [\[9\] **A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.** PubMed / Annals of the New York Academy of Sciences, 2010-04. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/20536472/>)
- [\[10\] **TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD** ClinicalTrials.gov, 2026. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07487363>)
- [\[11\] **Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers** ClinicalTrials.gov, 2009. clinical trial registry.](<https://clinicaltrials.gov/study/NCT00832091>)
- [\[12\] **Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye** ClinicalTrials.gov, 2012. clinical trial registry.](<https://clinicaltrials.gov/study/NCT01393132>)
- [\[13\] **Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.** PubMed / Sports Medicine, 2026-04-12. review.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- [\[14\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[15\] **openFDA Drugs@FDA query for TB-500 and thymosin beta-4** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22TB-500%22&limit=1>)
- [\[16\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[17\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration, 2025-11-20. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[18\] **Thymosin beta4 enhances the healing of medial collateral ligament injury in rat.** PubMed / Regulatory Peptides, 2013. animal.](<https://pubmed.ncbi.nlm.nih.gov/23523891/>)
- [\[19\] **Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts.** PubMed / Journal of Biochemistry, 2011. animal.](<https://pubmed.ncbi.nlm.nih.gov/20880960/>)
- [\[20\] **Thymosin beta4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury.** PubMed / Current Medicinal Chemistry, 2020. review.](<https://pubmed.ncbi.nlm.nih.gov/31333080/>)
- [\[21\] **Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction** ClinicalTrials.gov, 2022-07-20. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05485818>)
- [\[22\] **Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development.** PubMed / Mechanisms of Ageing and Development, 2004-02. animal.](<https://pubmed.ncbi.nlm.nih.gov/15037013/>)
- [\[23\] **Potential role of thymosin Beta 4 in liver fibrosis.** PubMed / International Journal of Molecular Sciences, 2015-05-08. review.](<https://pubmed.ncbi.nlm.nih.gov/26006229/>)
- [\[24\] **Thymosin Beta 4 Inhibits LPS and ATP-Induced Hepatic Stellate Cells via the Regulation of Multiple Signaling Pathways.** PubMed / International Journal of Molecular Sciences, 2023-02-08. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/36834849/>)
- [\[25\] **Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5xFAD mice: A potential therapy for memory improvement in Alzheimer's disease.** PubMed / International Immunopharmacology, 2026-02-01. animal.](<https://pubmed.ncbi.nlm.nih.gov/41443105/>)
- [\[26\] **Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.** PubMed / Stem Cell Reports, 2025-09-09. animal.](<https://pubmed.ncbi.nlm.nih.gov/40816274/>)
- [\[27\] **Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.** PubMed / Cardiovascular Research, 2025-12-31. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41229390/>)
- [\[28\] **Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases** Frontiers in Oral Health, 2026-09-30. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/42876687/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Endogenous fragment peptide

**Tier**

C

**Evidence**

52% Emerging

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[28 citations](<https://pepflow.app/peptides/tb-500/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Wound healing and ocular repair
- Cardiac tissue repair
- Soft-tissue recovery
- Tendon and ligament repair
- Alzheimer's-related neuroprotection
- Muscle repair and recovery
- Reduced inflammation and fibrosis
- Hair regrowth

### Common side effects

- Injection-site irritation

### Also known as

- Thymosin beta-4 fragment
- TB4 fragment
- Ac-LKKTETQ
- Thymosin beta-4 17-23 fragment

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [TB4 Frag 500: A Guide to Research, Dosing, and Safety](<https://pepflow.app/blog/tb-4-frag-500/>)
- [TB-500 dosage guide](<https://pepflow.app/peptides/tb-500/dosage/>)
- [GLOW Stack](<https://pepflow.app/stacks/glow-stack/>)
